At present, the field of consumer level gene testing has become a fast growing market. However, there has been a lot of questioning in the field, and how much can genetic testing bring to consumers? Recently, a company founded in 2016 in the American Gulf of San Francisco, known as Exploragen, is about to launch a lifestyle based on the customer DNA APP. Let's hear what the company's executives say......Can the lifestyle APP based on DNA really integrate into our lives?The company CEO Ron Andrews said the company has developed a high-throughput sequencing based on user data APP (NGS), so as to provide biological sleep features to users, and other indications of caffeine metabolism related personalized advice.Untitled -41.jpgAPP concept map, pictures: ExploragenOn the company's website, we've been able to see some of the information about the APP, called SlumberType. As a lifestyle related APP, users can understand the DNA and their sleep patterns have a kind of contact, such as sleep duration and sleep quality, and a person is born "early bird" or "night owl". It also includes additional tools for tracking and managing sleep, such as gadgets called "sleep sounds" and personalized alarm clocks."The use of biology, genomics data and machine learning tools, we can explore some very interesting things, let DNA not only become interesting and close to life, and inspire people to use DNA to improve their way of life. For example, genomics, nutrition and physical education will play a role in nutrition and fitness. All this information will allow customers to perform better for longer periods of time. In addition, we provide more than just a genetic report that tells you what genes you have. It's a dynamic form of service, which means that we have unique interactive capabilities that allow customers to leverage our genetic data to improve our daily lives." The company said CEO Andrews.Exploragen expects to launch the APP at the end of this month, ahead of time at another company, Helix, which is also involved in APP development. It is reported that, Helix company will officially launch its own APP in August this year. Helix company is headquartered in San Francisco, has been with the National Geographic, the Mayo Clinic, Duke University, Good Start Genetics, Exploragen, Vinome, Invitae and Mount Sinai institutions signed an agreement and cooperation for the development of APP corresponding to the interpretation of DNA customers in health, nutrition, origin, health care and other background. In addition, Helix will introduce some recreational products, such as a wine and DNA can match the application.Untitled -42.jpgThe company's core team, ExploragenDetection of consumer grade gene, the public how to weigh?For now, most of the public are reluctant to accept DNA based products. Some people will be afraid of this product because it is related to disease risk, and there are some people who are worried about the use and safety of data. Therefore, Exploragen's goal is to create an environment in which customers will explore their own data in a consumer way.In recent years, with the consumption level of gene detection becomes more and more popular, these specialized for detecting gene pedigree and progenitor genes, such as 23andMe, AncestryDNA, Family Tree DNA, the database has been expanded to millions. At the same time, more data links genetic data to lifestyle decisions, which also provides Exploragen with the resources to develop APP.Consumer level genetic testing: a good sense of good!Gadelrab said: "although we started in the" public place of fear ', but I think that 23andMe and Ancestry have the public gradually brought a kind of consciousness that we can learn something from the other genome. We have reached the critical point of utility and fear, and once the utility is more than feared, we will see explosive growth in the field of consumer level gene testing."However, when this product into the consumer market, Exploragen will undoubtedly be in doubt, not only those who worry about their genetic data of population, the outside world will also provide advice on the accuracy of APP is questioned.Gadelrab, director of business strategy at the company, said the peer review will be transparent for scientific research for APP development. In addition, she says, customers who choose to buy APP are more likely to be interested in the experience they offer, not how powerful the science behind them is."Now, genetic knowledge has been applied to the field of medicine, and its clinical usefulness and analytical validity must be supported by strong data," Gadelrab added. The information must be correct because the doctor will make medical decisions based on the information. But in the consumer world, people are willing to compromise on the data behind the premise that the data must be transparent. Our target audience is the people who are interested in the new experience, not the statistics."As time goes on, more and more people will make genome sequencing, and consumption level gene testing will become better and better, and the utility will be further improved. On the long road ahead, however, the voices of support and doubt will continue to coexist. For consumers, it's good to be able to choose and view gene testing products sensibly!

On July 19th, the Ministry of human resources and social affairs released the results of the medical insurance catalogue access negotiations. With 7 varieties of competition and price estimates of sales income changes, recommend focusing on competition, the market has a large space, the exact clinical effect varieties listed companies Hengrui medicine (apatinib), Kang Hong Pharmaceutical (Xipu, Compaq) (Xin Litai, Lisa Staw).According to the Ministry issued "on the 36 kinds of drugs included in the national basic medical insurance, work-related injury insurance and maternity insurance drug list B range notice", 36 kinds of drugs were included in the negotiations in 2017 the new national Medicare B range, and simultaneously determine these drugs of medical insurance payment standard.Price range is generally large, concerned about the large varieties of domestic enterprises to benefit. The average reduction in the health care negotiations at about 40%, the enterprise price change strategy can work, yet to be verified. Focus on the 7 varieties of domestic enterprises to benefit: for Grillo, recombinant human prourokinase, recombinant human brain natriuretic peptide, alli medoxomil, apatinib, Con Buter Heap, compound Huangdai tablets.Mostly for exclusive products, a good competitionFrom the generic drug situation, alli medoxomil apatinib, Con Buter Heap, and compound Huangdai tablets are the original research exclusive varieties, there is no generic declaration; recombinant human Pro urokinase and recombinant human brain natriuretic peptide is only one of the companies in the reporting of clinical, in the short term of the original research enterprises have little impact; there are only for Grillo AstraZeneca's original products, domestic listed companies sheenlip Taihe Pharmaceutical Group Pharmaceutical is expected to will be listed at the end of the year, with generics price advantage challenge the original research status of enterprises.The patient pays a substantial decrease in fees and increases willingness to use. Taking into account the price decline + class B average reimbursement of 80%, the patient pays down more than 80%.For the clinical effect is good, but because of the price reasons for the use of less drugs, patients will increase the will to use. The penetration rate of these drugs, especially the exclusive varieties, will increase rapidly after the inclusion of health care.Manufacturers to price change, long-term sales revenue increased significantly. Without regard to changes in sales, the price impact on the short-term income of the factory is self-evident. But if the composite price, sales volume change, 2018-2020 annual sales revenue will be significantly improved estimates into Medicare, apatinib, Con Buter Heap, ticagrelor, alli medoxomil future has the potential to grow into 1 billion or 2 billion varieties. Taking into account these products have not yet peatlands, gross margin to further enhance the space, temporarily consider the impact on the company's gross profit.Investment adviceWith 7 varieties of competition and price estimates of sales income changes, recommend focusing on competition, the market has a large space, the exact clinical effect varieties listed companies Hengrui medicine (apatinib), Kang Hong Pharmaceutical (Xipu, Compaq) (Xin Litai, Lisa Staw).

Since the implementation of the comprehensive reform of medical separation in April 8th, it has been full of 100 days. Yesterday, the Beijing Municipal Health Planning Commission Director Lei Haichao introduced a hundred days of medical reform related circumstances. 100 days, Beijing completed 60 million people medical service, emergency department in three hospitals was reduced by 12.7%, and the level of grassroots medical and health institutions for treatment increased 10%, three level of hospital average hospitalization days shortened 1.6 days. In the cost, since the reform of health care, Beijing region average daily medical expenses 35 million yuan.The number of emergency visits in grade three hospitals decreased by 12.7%Health care reform operation 100 days, the city has completed 60 million people medical service, 3100 medical reform in the medical institutions running smoothly. Daily monitoring information showed that outpatient services at grade three hospitals had decreased by 12.7%, and the highest time had been reduced to 16%." Lei Haichao said, two hospitals also declined, and primary medical and health institutions and the level of hospital diagnosis and treatment volume has increased significantly, an increase of 10%.In grade three hospitals, the number of doctors in different ranks has also changed. Overall, after the reform, the number of deputy chief physician outpatient visits dropped by 10%, the chief physician dropped by 22.7%, and the number of outpatient visits of well-known experts dropped by 15.2%. "You can see that we are more rational in seeing a doctor, not blindly pursuing the expert number.". It also alleviates the need for registration of patients who really need specialist numbers, making our expert resources more useful for the treatment of difficult and difficult cases than for our specialists to see common diseases and common diseases."The average length of stay decreased by 1.6 days in 100 days. Lei Haichao said that in March, the average length of stay in Beijing was 8.1 days, and has been stable for 6.5 days. "If there were no reform measures, it would take about 10 years for the average hospitalization rate to be shortened by 1.6 days. The shortening of hospitalization rate is helpful to strengthen the three grade hospitals to pay attention to the treatment of difficult and severe diseases and to improve the medical service in hospital".An average of 35 million yuan per day to save medical expensesAfter the medical reform, acupuncture, massage and other parts of the cost increase, will not bring the overall cost of medical treatment increased? Lei Haichao said, according to estimates, 100 days, Beijing saves medical expenses as high as 3 billion 500 million. "Beijing began to reform in April 8th, and in the second half it is even higher than in the first half.". Around the year, about 9 billion 500 million of the cost will be saved, which means saving medical expenses for the Beijing area 35 million per day." Lei Haichao says.In addition, the cost of drugs, the procurement of sunlight to achieve the drug savings of 1 billion 370 million, the cumulative average price of drugs dropped more than 8%. Lei Haichao said that after April 8th began medical reform, the procurement of drugs sunshine has generated 17 billion 200 million market transactions. It is estimated that the cost of pharmaceuticals will be over 3 billion yuan in the whole year. Among them, the proportion of drugs in two or three hospitals dropped from 42.2% to 34.4%, the current downward trend is still continuing.Two months and 8300 prescriptionsBeiqing Bao reporter learned that, for the city's 3 million high blood pressure and diabetes patients commonly used 105 kinds of chronic diseases, in the community has been delivered in place. Lei Haichao said that at present, the community implemented two months long prescription system, the elderly do not go back and forth medical institutions. "Long prescription has opened more than 8300, the family doctor key crowd signing rate has reached 73%, the signing rate in the reform process of 100 days to achieve a significant jump."."How do patients view this series of reform measures? NBS Survey Office in Beijing recently in two or three hospitals for the intercept interviews of 600 patients visit, 91.7% of the patients expressed support for the comprehensive reform of Beijing medicine separate, the other 82.2% patients that now the reform policy is conducive to the diagnosis and classification. 83.8% of patients had a positive attitude toward medical fees, and 63% felt the cost was flat or lower during the visit.Medical supplies are expected to further reduce pricesThe next year, Beijing will further promote the reform of health care initiatives. For example, the performance evaluation of public medical institutions, has designed 11 key performance indicators to all two or three hospitals in Beijing area were analyzed, including hospital antimicrobial drug use rate and low risk of disease mortality and 30 day readmission rate, average hospitalization days, utilization of beds, outpatient the average patient medical expenses, medical expenses, medical expenses are increased, the proportion of drug and material such as inpatient. At the same time, the salary distribution policy of medical staff in Beijing area will be studied.In addition, Beijing, Tianjin and medical supplies joint procurement will start, is expected to achieve further decline in supplies. Lei Haichao said: "compared with the organization and coordination of procurement in one place, the difficulty of joint procurement between the three places will be greatly improved.". At present, the city is working closely with Tianjin and Hebei, on the one hand to obtain medical consumables market use information, on the other hand, we should consider how to achieve joint procurement through the efficient organization of three places."

Familiar with the DR industry all know, in recent years, too many words of war. As the upstream supplier of DR industry, we are not just watching, but very tangled, very painful.A complete industry chain should be in the benign competition environment. 4-5 years ago, the DR industry ushered in a golden period of development, when the country vigorously promote the die upgrade, we as the core component suppliers, operating costs are relatively low in all aspects, profits naturally good. The start of the 13 year, but good times don't last long, this is not the industry, can be said to be in the flames of war, and is an innovative competition, is to rely on price war against. Down the stream, we have to be forced to go down. 14 years ago, the domestic initiative to promote the dynamic DR this product, to be honest, I personally think that this product has given hope to the industry, but also gave us new opportunities.Dynamic DR, not just a new product, but a new category, is a new technological revolution, saying that he is "industry life-saving straw", not too much. People do not understand, genuine debate may every day will make up a row of dynamic DR. In fact, the focus of the current battle of words in this "true and false debate" in. As an upstream supplier, I personally feel that from the industry as a whole, there is a real need for literacy in the industry. Not only for users of literacy, but also for our downstream vendors literacy, for our core component suppliers as well as literacy.To say that a product is true or false must always have a standard. I see a lot of the arguments, like the evil wife abuse, trouble. So far, the industry did not give a definition of dynamic DR, so many daughter-in-law was also seems to understand, but should not overdo sth.. I personally integrated the development of the industry over the past two years, the individual feel that there are several standards should be everyone's consensus.Can the first, first new technologies really have clinical applications?Second, can these functions really solve clinical problems?Third, is this product more and more user?Fourth, whether the technology has wider space for development?First, does dynamic imaging really have clinical applications?The profession has the conscience, understands the product, knows that this product application should all be clear, the dynamic DR most core application lies in the accurate diagnosis, it derives many kinds of clinical application function. For example, we are familiar with the "visual positioning high-definition film", high-definition film, large format perspective, video preservation, playback, visual contrast, automatic exposure control, body stitching function".These functions require multiple devices in the past, and now a device has a variety of integrated applications. This is not a simple integration, it is achieved through technical breakthroughs. Because it is not like a double bed double tube, simple sharing of a high-voltage generator, not as a combination of gastrointestinal machine plus flat, but the use of a dynamic detector, to achieve all the functions. Functionally, dynamic DR is all the functionality that has clinical needs.Second, dynamic DR these functions can really solve the clinical problems?The various functions of dynamic DR have been analyzed. How about the clinical performance? On the face of it, dynamic DR does have some of the properties of static DR, as well as some of the attributes of the gastrointestinal machine. However, static DR the past belongs to blind shoot, mainly rely on experience technicians to operate; gastrointestinal machine format is small, the contrast is too low, the pixel difference, is not conducive to accurate positioning, can only be carried out extensive examination of some general lesions. Dynamic DR integrates two functions and is higher than both. Reflected in the perspective of the location, and then real-time HD film, so as to solve the problem of blind shot, the film is more accurate; the large format clear perspective, observe the time reduced dose reduction of lesion HD film, so as to solve the problem of fuzzy positioning. For example, dynamic DR is used in the examination of tracheoesophageal fistula. Dynamic DR has the functions of large format fluoroscopy, instantaneous high-definition patch, video image playback and frame extraction. During the esophageal iodine contrast examination, the image of the lesion can be captured in real time due to the rapid flow of contrast media. Some patients because cough obvious, should not be repeated many times inspection, dynamic DR video playback, image extraction frame function, can collect characteristic image, clear diagnosis, more can avoid iatrogenic injury, ensure medical safety.Third, dynamic DR product users are not increasing?In the sales follow up Chinese digital imaging equipment China Ipsos every month from 2014, we found that the statistics he the overall development of the total number of dynamic DR less, but the speed is fast. Of course, there is the role of enterprise marketing capabilities. In 2015, manufacturers more and more dynamic DR, the number of sales is a geometric increase in light, domestic manufacturers of sales exceeded 500 units; in 2016, an enterprise in Shenzhen, one of its dynamic DR sales of hundreds, and in 2017, the company's sales have been the cumulative number of nearly 1000. From the manufacturer's sales volume and the number of enterprises entering the field, the product has gone through the death trap of new product promotion and officially entered the stage of development. To analyze, from the user's level can be found, the product of a change in the past Pyramid sales model, there are users in the big three, people's Hospital, county level public hospital and private hospital, the overall retention rate and various levels of hospitals accounted for roughly the same number ratio, indicating that the products

Today (July 25th), Johnson Corporation (Johnson & Johnson) announced that its Janssen Pharmaceutical Companies vaccine in the field of HIV-1 has achieved its first clinical (APPROACH study) data.Humans have been in contact with HIV / AIDS global battle has made significant progress, including the development of a key role of antiretroviral therapy and HIV prevention tools, but the disease is still one of the most serious threat to global health of our times. At present, a total of 37 million people worldwide suffer from HIV infection, nearly 2 million new infections each year. Because of the unique nature of the HIV virus, including its genetic diversity and the ability to mutate rapidly, an effective HIV vaccine has not yet been obtained.Since 2005, Janssen's vaccine prevention division has been involved in the integrated preclinical / clinical AIDS vaccine development program (IPCAVD) supported by the NIH. The APPROACH clinical study uses a class of vaccines based on mosaic mosaic technology that contains immunogens from various HIV virus subtypes that cause HIV-1 infection worldwide. These immunogens were based on Janssen, a adenovirus based serotype 26 (Ad26) AdVac technique, delivered via viral vectors. Then, virus vector and soluble protein composition, the formation of chimeric vaccines: they strengthen the initial scheme first by the immune system response, and enhance the immune system, the ultimate aim is to produce a more powerful and more lasting immunity.In preclinical clinical studies, the inclusion of mosaic type chimeric vaccines proved to prevent infection with HIV like viruses. The most effective initial strengthening programme in these studies reduced exposure to infection by 94% and resulted in 66% complete protection after six exposures.APPROACH (HIV-V-A004 / NCT02315703) in the United States, Rwanda, Uganda, South Africa and Thailand, is a multi center, involving 393 cases of healthy *****s were not infected with HIV virus, randomized, placebo-controlled, double-blind clinical study 1/2a. It is assessing the safety, tolerability, and immunogenicity of various mosaic type initial enhanced HIV-1 vaccines. All vaccine regimens appear to be well tolerated. The primary analysis after the third vaccination showed that most active vaccine protocols triggered antibody responses in 100% of the study participants.The immune response observed in APPROACH based, and observed in preclinical studies of the protective effect, combined with the pilot scheme of gp140 HIV-1 vaccine candidate Ad26 chimeric soluble protein Janssen and Clade C are selected as further proof of concept phase 2B efficacy (proof-of-concept efficacy) on the basis of. If the study goes ahead, Janssen and its global partners are expected to carry out the survey in southern Africa at the end of 2017 or early 2018.Untitled -2.jpgDr. Paul Stoffels, chief scientific officer at Johnson Inc. (photo source: Johnson Corporation)"In recent years, new optimism has surfaced: we will probably find an effective HIV vaccine against AIDS in our lifetime," said Paul Stoffels, chief scientific officer at Johnson. The findings of today's announcement reinforce this belief and we look forward to moving forward to the next phase of clinical development."

Recently, China's Harbin Institute of Technology has led the development of a new type of robot that can swim in human blood vessels and target drugs. This article was compiled from New Scientist, entitled "Tiny robots swim the front crawl through your veins" article.It's not a swimmer, Michael Phelps, but this tiny magnetic robot can move in liquid at 10 microns per second. It is small and powerful enough to deliver drugs from human veins through more viscous liquids, such as blood.Freestyle is the fastest way for humans to swim. So Tianlong Li and his colleagues at the Harbin Institute of Technology in China let game robots mimic the action.Each nano swimmer is 5 meters long and has three main sections, such as two silver hinge sausages connected together. The body is made of gold, with two magnetic arms made of nickel on either side, and a magnetic field applied to the micro robot to move the arm.As the researchers switched the magnetic field back and forth, the nano swimmer's arm rotated and pushed forward, just like a swimmer's arm crawled forward in freestyle."The invention is exciting because of its speed and small size and the same size as the blood vessels," says Eric Diller Diller of University of Toronto in Eric, canada. It's small enough to basically go anywhere in the body."Because body fluids are thicker than water and are difficult to swim through, researchers have tested their nano swimmers in serum. A robot can swim only 5.5 microns per second, but still faster than other similar micro machines.For the delivery of targeted drugs without invasive surgery, these nano swimmers can be coated with drugs and injected into the bloodstream, which can be roughly controlled by an external magnetic field.Because of the small size, individual nano swimmers will not be able to carry enough drugs to actually help. "Maybe we'll have to use one thousand robots," Diller said. "We can't track all these robots, so there's a lot of security and toxicity."In the future, these micro machines must be made of biodegradable materials for use in the bloodstream. But, says Diller, clinical trials can begin in the next five to ten years for less complex areas such as the urinary tract or the eye. A single swimmer is injected into the eyeball where the drug can be delivered directly to the retina and removed, which is much easier than allowing a team of swimming robots to enter the circulatory system.

At the 2012 Sundance Film Festival independent science fiction film, "robot and Frank" won the Alfred Sloan award. The film tells the story of a mild dementia occurs between robot story, story writer for the preset time is "coming in the future".In fact, this "future" has quietly arrived.The machine "care" skillsTOYOTA, a Japanese carmaker, recently shared a video showing its new robot. The robot, 1.22 meters tall, has a clip on arm, and a wheel base can move over a flat ground. In the video, users can use the tablet computer to control the robot to pour tea. TOYOTA called the robot "support robot", a robot dedicated to helping disabled people achieve simple living.It is understood that, in response to the aging population, TOYOTA and other companies are committed to research and development of one of the power of robots. In 2013, the government designated 24 enterprises, 2 billion 390 million yen subsidy, to develop nursing robots, which will help elderly people move, toilet and report their whereabouts in the room. In designated companies, TOYOTA automotive develops robots that move older people. Japan's Ministry of economy, industry and industry said that in 2018, each elderly family or three or four households, one has at least one nursing robot.Not only in Japan, but also in China, the pension robot has also begun to be popularized. Hangzhou, Ji'nan, Tianjin and other social welfare institutions and nursing homes have been the introduction of "Nursing Robot", to accompany the elderly chat boredom. The robot is connected to the sensor to detect an accidental fall of an old person. If an accident occurs, it sends an alarm signal to the manager via sms. Family members or nursing staff to camera function through remote operation robot mobile phone and tablet computer, network equipment, to understand the situation and take the rescue.Into the family was questionedThe old age robot has stepped into people's life and played an important role in making up for the manpower. But can the retirement robot really be as close as a person to serve the elderly? Can they really take care of old people? Moreover, intelligent "care" into the family, is more difficult to cross the people's moral and psychological barriers. Just as social media such as WeChat and micro-blog have just emerged, people are questioning that they will lead to alienation between people. Almost every revolution in technology can lead to panic about alienation."For robot workers, we must ask: more robots in the isolation of human, or really help people?" University of Edinburgh robotics center director Professor Parsons pointed out that "the use of robots has also led to concerns about personal information. The quality and personalized service of the robot is directly proportional to the amount of data you are willing to release to the system, and your data will be exchanged for better robot services."In addition, although the robot can in some function instead of even beyond children and workers, but emotionally unable to replace humans. In one, "will you keep the robot company with the parents?"" In the survey, the netizen "laughing and joking pony" said: "parents have been suffering before, and they are hard to bring us. Why can't we stay with them in the same way?" Robots can never take the place of children."There is no denying the fact that robot technology has its drawbacks. Especially for the "elderly robot", in the identification of drugs, and human interaction, precise action, there is a high degree of accuracy requirements. Although these functions are technically available, there is still considerable uncertainty about the success rate of identification.Little machines have great potentialThe United States Census Bureau in March 29, 2016 released a report called "a growing old world: 2015" report, by 2050, the global aging population over the age of 65 the proportion of the total population will double, the number will be 2.5 times more than the current. The tremendous pressure of population aging has promoted the development of intelligent robots in the field of nursing and retirement.From our experience, medical care field is currently one of the most popular Android application development in vertical field, the world's best engineers and managers have to see the huge potential of the robot in solving the global problem of aging." In addition to the "manpower shortage" factor, reducing the overall cost of medical care is also an important goal for the future of the robot in the field of care.But some experts believe that there are some difficulties in the development of the old age robot. Dun Xiangming, a member of the National 863 service robot research group and an associate professor of Robotics Research Institute of Shanghai Jiao Tong University, lists the security issues in human-computer interaction as the first priority. In Dayton Xiang Ming view, the global civil robot is still emerging areas. Because of the individual and environmental differences, interactive security is a global problem to be solved, so most of the products are still in the laboratory research and product testing stage, and the production time is not yet ripe.Looking at the domestic robot industry development plan, the national development and Reform Commission issued in 2016 "(2016-2020)" also mentioned the "intelligence Nursing Robot", and it is listed as a symbol of focus on the development of products, pointed out the need to promote the professional service robot series, personal and family service robot to achieve commercialization.According to Analysys International day before the report, 2016 China Chi

When we talk about robots, you naturally think of humanoid robots that you have seen on the screen.But many robots are more like machines that can operate independently, especially in the field of medicine. And they are likely to have a major impact on our lives.For example, a 3D printing robot called Stormram 4 can perform biopsies, that is, remove a cell tissue from human skin for examination. The design was designed to treat women's common cancer, breast cancer.The key difference is that it can be performed in an MRI scanner rather than during an ultrasound or breast X scan. According to researcher Fran oise Siepel C robot, the robot has compared to those used in the imaging accuracy of breast cancer imaging techniques in the diagnosis of higher.Of course, not only you, but it sounds good to me. Held at the end of June the British robotics week, this robot to victory in the challenge and surgical robot. But I recently used ultrasound guided breast biopsy, rethink the application of robot in the medical aspects of this experience so that I had to, because in order to improve the diagnostic technology, the robot may ignore a key factor.Human factorFirst of all, breast biopsy is a very serious matter. Before you have a biopsy, the doctor usually checks you out to make sure you're not guessing. The biopsy will cause the patient to be very worried about the operation because the patient does not know what the outcome will be.Secondly, in the diagnosis process, although I'm not afraid of injection, but the biopsy needle is really big. It is not like the needle used in normal injections. I think if it scares me, then it scares people too.I didn't dare to see the needle puncture my skin, but thanks to the radiologist, I had the courage to see it on the ultrasound screen. He took what we were in, where he told me all the reasons and acupuncture treatment. He explained to me every step of the process and explained when the needle would take the sample and how I would feel when taking the sample.That's why I have reservations about the Stormram 4 robot. Someone to share with me and reveal to me the whole process will ease my anxiety.Some women are afraid of injections, and some women are claustrophobic and don't like mri. In addition, fear of accepting unknown diagnosis results, so they may show extreme anxiety.When I told Siepel about my worries, she said, "we fully understand that the biopsy is a potentially painful experience because the diagnosis is uncertain before the unknown.". Therefore, during an MRI, the radiologist will interpret the process with an audio link to the patient."In addition, doctors recommend narcotics.Even if the doctor is not with you, it is very reassuring to hear a radiologist speak in your ear. If I have other options and these two options can provide the correct results, I'd prefer to have an ultrasound guided X ray examination, so that the doctor will be able to stay with me.But that's the problem - the results they provide are different. Compared with ultrasound, MRI can locate the needle more precisely.An assistant, not an alternativeAs robots play a more and more important role in modern medicine, the interaction between patients and robots is very important. Wachter data ethics researcher Sandra Alan Turing Institute said: "through educational activities to ethical values into the whole process of the research, this is the robot experts are working to solve things, which makes me feel at ease.""I talked to a lot of people in this field, and they became increasingly aware of the meaning of ethics in their work," she said. This mode of thinking is changing to ethics. All jobs are more or less ethical, and robot learning and robotics in the natural health care system are no exception."The primary role of robots in modern medicine is to assist rather than replace doctors; in other words, they enhance the capabilities of doctors. "Robotics can help reduce the number of surgeries throughout the procedure and improve safety, but it will always take someone to monitor the process," Wachter said."Perhaps in the future, as robots become more common in surgery or other medical procedures, there will be trade-offs between the treatment process and the outcome, but we want both to achieve the greatest degree of optimization.Wachter said: "if we pay enough attention to ethical concepts, then it will have a great impact on medical technology."."

One of the world's fifth largest medical device companies has achieved good results in China, but it is pulling out of the Chinese market!Withdrawal from China is basically confirmedWill that China news spread everywhere in the industry that Kant's music, in July 21st, WeChat released the official music China Kant "on Kant's music Chinese business" article, not to "exit Chinese" message rumor, it will exit the Chinese basic facts prove.The same day, blue lie and Candler related executives exchange, the other did not deny that China will exit. The executive's statement is consistent with the official WeChat caliber.He said that since the acquisition of Chinese enterprises Candler, business growth has been very good, far exceeding the average level of the industry. At present, health care reform has entered a new stage, the company to grow, there is a strategic breakthrough, which should be considered by the company's policy makers. In the past, Kant's business in China was very practical, and this time the adjustment will also be aimed at strengthening competitiveness.Earlier, Reuters revealed that Kant intends to sell its business in China, the transaction price is expected to be between 1 billion 200 million and ~15 billion dollars. Shanghai pharmaceuticals, Huarun pharmaceuticals and Sinopharm are three of the many companies that want to buy Kant's China, and will make their choice on Friday (July 22nd).But after two days, no further information was received, and whether or not the decision was made last Friday remains unknown.The business world rankings, Kant Locke fifthAccording to Medtech Insight (MedTech observation) in 2016 to the world medical device companies in the sales ranking, cardinal medical equipment business with $12 billion 430 million in the world medical device company Fifth, behind Medtronic, Johnson, GE, SIEMENS.According to July 20th just Chubang the "fortune" Global 500 ranking, Candler in 2016 to $121 billion 546 million in revenue ranked thirty-fifth, more than in 2016 increased by 15, in the field of health after the United Health Group and CVS.In the field of medical equipment, Candler bought Johnson's Cordis for $1 billion 900 million in 2015, thus entering the field of equipment production. Cordis is strong in interventional vascular technology development and manufacturing, and it provides diagnostic and interventional products, including diagnostic and interventional catheters, balloons, self expandable stents, guidewire and vascular closure devices, etc..In April 18th, Candler announced a $6 billion 100 million acquisition of Medtronic's medical equipment business, and signed an acquisition agreement, payment of cash.Candler, China Medical DevicesEnter the Chinese cardinal in 1993 2003 formally approved the pharmaceutical distribution license, acquire the license for the first foreign; since 2005, expanding into medical devices and OTC business; in 2010, to $470 million acquisition of Shanghai pharma.In 2012 China established cardinal cardinal medical equipment consulting (Shanghai) Co., Ltd covers a wide range of products, the main concern of medical consumables, such as clothing, non-woven surgical gowns, syringes, surgical cotton etc..It can be said that the cardinal in 2007 China, accelerated in China business expansion through mergers and acquisitions or self run companies, successively in Hubei, Chongqing, Chengdu, Wuxi, Ningbo, Shenzhen, Dalian, Guangzhou, Tianjin, Wenzhou, Guizhou etc. in distribution.At least before September 2016, according to the match Bo blue instruments, music in the medical device business China Kant reflected or aspiring and its turnover, estimated in the billions of yuan, the distribution in the field of Chinese medical equipment, should have entered the top four; it also rely on the parent company based in the United States and the global market distribution ability willing to help China medical equipment manufacturing enterprises to go abroad, into the European market.Why quit China?A person who has been engaged in the management of the staff in Kant's music to match the blue Bai said, in 2014, during 2015, cardinal Chinese or complacent, to do a big business, but by 2016, all of a sudden a lot of calm feeling.His analysis, Candler could have grasp of policy is not very good, that Chinese will press the mode of medical policy development in the United States, but in fact China policy has its own unique side, and the change of policy may have unexpected cardinal.Kant music before Chinese acquisition for medical wholesale enterprises, a high dependence on the hospital, in 2016 two votes after the opening, only wholesale has no hope, to the future, so consider stripping China business.In the past few years, the acquisition of drug retail business, he said that Kant's acquisition after the transformation of the business, affecting the retail business profit margins, margins are not as great as the outside world think.And with the cardinal Chinese exit, the business that will most likely be on the drugs, Chinese medicine or medicine in a Huarun, the medical device business nature will be transferred.

AQSIQ, the State Commission for Supervision held a press conference on 14. By the end of 2016, there were 33622 certification, inspection and inspection institutions nationwide, an increase of 7.02% over the previous year.Industry structure, layout optimization, market-oriented mechanism is emerging. At present, China's enterprise system inspection and testing institutions 21012, accounting for 63.22% of total institutions; institutions 11479, accounting for 34.54% of total institutions; other legal types of 744, accounting for 2.24% of the total amount of institutions. Since 2013, the proportion of inspection institutions in China's institutions has changed from 42.5% to 34.54%, showing a gradual downward trend.